Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of ...

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

Twice-a-year-PReP will only fulfill its potential if Medicaid takes decisive action to ensure it is accessible to the ...

The results support the idea that certain ... New Drug Shows Promise in Clearing HIV from Brain July 25, 2024 — An experimental drug originally developed to treat cancer may help clear HIV from ...

Patient and public health groups worry about a potential patent grant to Gilead Sciences for the HIV drug lenacapavir in ... infections every year, with one new HIV infection every 24 seconds.

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can ... but the molecular mechanisms responsible for negative clinical observations are unknown. A new study ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company wi ...

Dr Bianca Ogden and Hashan De Silva share the companies and trials they find interesting in the constantly innovating biotech ...

2024, 7, 8, 2379-2390) Efavirenz is an important drug for treating HIV infection ... a UMBC bioanalytical chemist and senior author on the new paper. “That formed the basis for investigating ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...

represents a dramatic new alternative to the current standard of care for HIV prevention: taking a pill called Truvada every day. While this type of drug, called pre-exposure prophylaxis (PrEP ...